More than 1,5 years ago, Steven Powell became the CEO of the VUB spin-off eTheRNA. Since then, Powell has been working on an ambitious business plan for the company. With the second round of capital where it raised €34M, eTheRNA wants to further develop its pipeline for cancer therapies and infectious disease treatments.
ETherNA recently formed a consortium with North American and European partners to develop the vaccine against COVID-19, based on its messenger RNA (mRNA) technology.